Related Experiment Videos

Resistance to anti-human immunodeficiency virus therapeutic agents

¹Department of Antiviral Research, Merck Research Laboratories, West Point, PA, USA.

Advances in Experimental Medicine and Biology

|January 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.

Vaccine·2015

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants.

Vaccine·2011

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.

Vaccine·2011

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2008

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

Bioorganic & medicinal chemistry letters·2001

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

Bioorganic & medicinal chemistry letters·2001

See all related articles